NASDAQ:ASBP Aspire Biopharma (ASBP) Stock Price, News & Analysis $0.34 +0.00 (+1.23%) As of 09:03 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFDA EventsOwnershipSEC FilingsTrendsBuy This Stock About Aspire Biopharma Stock (NASDAQ:ASBP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aspire Biopharma alerts:Sign Up Key Stats Today's Range$0.34▼$0.3450-Day Range$0.24▼$0.5252-Week Range$0.22▼$15.80Volume5,697 shsAverage Volume6.92 million shsMarket Capitalization$16.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico. Read More Receive ASBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aspire Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ASBP Stock News HeadlinesAspire Biopharma Announces Leadership Reshuffle Amid ResignationsJuly 30, 2025 | msn.comAspire Biopharma’s BUZZ BOMB Shows Promising Initial FeedbackJuly 25, 2025 | finance.yahoo.comGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. Backed by the government but powered by private corporations, this initiative paves the way for digital dollars—programmable, trackable, and outside your control. Once embedded into apps, banks, and retail systems, opting out may no longer be possible. But there’s still time to protect your financial freedom—if you act before the system goes fully live.August 8 at 2:00 AM | Priority Gold (Ad)Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and ...July 22, 2025 | gurufocus.comAspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB, its New Sublingual Pre-Workout SupplementJuly 9, 2025 | finanznachrichten.deAspire Biopharma announces ‘positive’ consumer feedback on Buzz BombJuly 9, 2025 | msn.comAspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin FormulationJune 24, 2025 | investing.comAspire Biopharma Holdings relocates headquarters to FloridaJune 20, 2025 | investing.comSee More Headlines ASBP Stock Analysis - Frequently Asked Questions How have ASBP shares performed this year? Aspire Biopharma's stock was trading at $0.4301 at the start of the year. Since then, ASBP stock has decreased by 21.5% and is now trading at $0.3375. Who are Aspire Biopharma's major shareholders? Top institutional shareholders of Aspire Biopharma include Procyon Advisors LLC (1.31%), Crewe Advisors LLC (1.27%) and Optivise Advisory Services LLC (0.47%). How do I buy shares of Aspire Biopharma? Shares of ASBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ASBP CIK1847345 WebN/A Phone(561) 704-8527FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.54 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-508.70% Debt Debt-to-Equity RatioN/A Current Ratio0.22 Quick Ratio0.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.17) per share Price / Book-0.15Miscellaneous Outstanding Shares49,526,000Free Float25,754,000Market Cap$16.51 million OptionableN/A Beta0.79 10 Stocks Set to Soar in Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:ASBP) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aspire Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aspire Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.